Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/mus.26903 http://scihub22266oqcxt.onion/10.1002/mus.26903 C7264534!7264534!32329921     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Muscle+Nerve 2020 ; 62 (1): 46-9 Nephropedia Template TP {{tp|p=32329921|t=2020. Spinal muscular atrophy care in the COVID?19 pandemic era |pdf=|usr=}}{{32329921}} gab.com Text Spinal muscular atrophy care in the COVID 19 pandemic era JO: Muscle Nerve http://www.kidney.de/pget.php?&tw=1&pmid=32329921 #FOAvip The coronavirus disease 2019 (COVID?19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID?19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID?19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic? or institution?specific policies and precautions for COVID?19. Twit Text FOAVip Spinal muscular atrophy care in the COVID 19 pandemic era ????Muscle Nerve http://www.kidney.de/pget.php?&tw=1&pmid=32329921 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32329921 #FOAvip English Wikipedia <ref>{{Cite pmid|32329921}}</ref> Spinal muscular atrophy care in the COVID?19 pandemic era #MMPMID32329921 Veerapandiyan A; Connolly AM; Finkel RS; Arya K; Mathews KD; Smith EC; Castro D; Butterfield RJ; Parsons JA; Servais L; Kuntz N; Rao VK; Brandsema JF; Mercuri E; Ciafaloni E Muscle Nerve 2020[Jul]; 62 (1): 46-9 PMID32329921show ga The coronavirus disease 2019 (COVID?19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID?19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID?19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic? or institution?specific policies and precautions for COVID?19. äSpinal muscular atrophy care in the COVID?19 pandemic era (epmc).pdf DeepDyve Pubget Overpricing